Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Randomized Double-Blind Placebo-Controlled Crossover Trial for the Diagnosis of Non-Celiac Gluten Sensitivity in Children

Francavilla, R MD, PhD1; Cristofori, F MD1; Verzillo, L MD1; Gentile, A MD1; Castellaneta, S MD2; Polloni, C MD3; Giorgio, V MD4; Verduci, E MD, PhD5; D'Angelo, E MD6; Dellatte, S MD7; Indrio, F MD1

American Journal of Gastroenterology: March 2018 - Volume 113 - Issue 3 - p 421–430
doi: 10.1038/ajg.2017.483
ORIGINAL CONTRIBUTIONS: COLON/SMALL BOWEL
Buy
SDC

OBJECTIVES: Non-celiac gluten sensitivity (NCGS) is characterized by intestinal and extra-intestinal symptoms that are related to the ingestion of gluten in subjects who are not affected by either celiac disease (CD) or wheat allergy (WA). In this multicenter study, we aim for the first time to evaluate the prevalence of NCGS in pediatric subjects with chronic functional gastrointestinal symptoms associated with gluten ingestion using a double-blind placebo-controlled (DBPC) gluten challenge with crossover.

METHODS: Among 1,114 children with chronic gastrointestinal symptoms (negative CD and WA), those exhibiting a positive correlation between symptoms and gluten ingestion were eligible for a diagnostic challenge including the following phases: run-in, open gluten-free diet (GFD) and DBPC crossover gluten challenge. Patients were randomized to gluten (10 g/daily) and placebo (rice starch) for 2 weeks each, separated by a washout week. The gluten challenge was considered positive in the presence of a minimum 30% decrease of global visual analogue scale between gluten and placebo.

RESULTS: Out of 1,114 children, 96.7% did not exhibit any correlation with gluten ingestion. Thirty-six children were eligible; after the run-in and open GFD, 28 patients entered the gluten challenge. Eleven children (39.2%; 95% CI: 23.6–53.6%) tested positive.

CONCLUSIONS: This is the first demonstration of the existence of NCGS in children that reinforce the need for a DBPC for the diagnosis as the diagnosis is ruled out in >60% of cases. The registration identifier in ClinicalsTrials.gov is NCT02431585.

1Interdisciplinary Department of Medicine-Pediatric Section, University of Bari, Bari, Italy

2Department of Pediatrics, San Paolo Hospital, Bari Italy

3Department of Pediatrics, Santa Maria del Carmine Hospital, Rovereto TN, Italy

4Department of Pediatrics, Catholic University, Rome, Italy

5Department of Pediatrics, University of Milan, S. Paolo Hospital, Milan, Italy

6Department of Pediatrics, Santa Maria Incoronata dell'Olmo Hospital; Cava dei Tirreni SA, Italy

7Tandoi Group Factory, Corato, Italy

Correspondence: R Francavilla, MD, PhD, University of Bari Aldo Moro, Interdisciplinary Department of Medicine-Pediatric Section, “B. Trambusti” Department Giovanni XXIII Hospital- Via Amendola 270 Bari, Italy. E-mail: rfrancavilla@gmail.com-ruggiero.francavilla@uniba.it

published online 30 January 2018

SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/AJG/A302, http://links.lww.com/AJG/A304

Received 17 July 2017; accepted 29 October 2017

© The American College of Gastroenterology 2018. All Rights Reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website